[
  {
    "ts": null,
    "headline": "Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease",
    "summary": "Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...",
    "url": "https://finnhub.io/api/news?id=70ed57fc5f0860ed913bd859776fe4e219f1fcafd5b7c36f10521e735d7f1a77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749770700,
      "headline": "Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease",
      "id": 135225005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...",
      "url": "https://finnhub.io/api/news?id=70ed57fc5f0860ed913bd859776fe4e219f1fcafd5b7c36f10521e735d7f1a77"
    }
  },
  {
    "ts": null,
    "headline": "Moderna RSV Vaccine Gets Expanded FDA Approval, Company Says",
    "summary": "By Daniel Papp Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased...",
    "url": "https://finnhub.io/api/news?id=cb3dc2ff6c092780a7bb86ab6e64bbac2355d834c5d031160aee54e9c9c6c7b4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749758768,
      "headline": "Moderna RSV Vaccine Gets Expanded FDA Approval, Company Says",
      "id": 135224270,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "By Daniel Papp Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased...",
      "url": "https://finnhub.io/api/news?id=cb3dc2ff6c092780a7bb86ab6e64bbac2355d834c5d031160aee54e9c9c6c7b4"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Says Received FDA Approval For RSV Vaccine, Mresvia, In Adults Aged 18-59 At Increased Risk For RSV Disease",
    "summary": "Moderna Inc: * MODERNA RECEIVES U.S. FDA APPROVAL FOR RSV VACCINE,MRESVIA, INADULTS AGED 18–59 AT INCREASED RISK FOR RSV DISEASE * MODERNA - INTENDS TO HAVE MRESVIA...",
    "url": "https://finnhub.io/api/news?id=f96c7e67e9965845c5074b2c4907f55fa91494bd277fc52ce8af1c600bf17299",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749758591,
      "headline": "Moderna Says Received FDA Approval For RSV Vaccine, Mresvia, In Adults Aged 18-59 At Increased Risk For RSV Disease",
      "id": 135224259,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Moderna Inc: * MODERNA RECEIVES U.S. FDA APPROVAL FOR RSV VACCINE,MRESVIA, INADULTS AGED 18–59 AT INCREASED RISK FOR RSV DISEASE * MODERNA - INTENDS TO HAVE MRESVIA...",
      "url": "https://finnhub.io/api/news?id=f96c7e67e9965845c5074b2c4907f55fa91494bd277fc52ce8af1c600bf17299"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults",
    "summary": "The U.S. Food and DrugAdministration on Thursday expanded the use of Moderna'srespiratory syncytial virus vaccine to a lower group ofadults aged 18 to 59 years at increased risk for disease. ...",
    "url": "https://finnhub.io/api/news?id=9e265169b6737d4fa92a811a1bd972b5793b8763d68240b88e58d12902bf1c2b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749757809,
      "headline": "US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults",
      "id": 135224197,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration on Thursday expanded the use of Moderna'srespiratory syncytial virus vaccine to a lower group ofadults aged 18 to 59 years at increased risk for disease. ...",
      "url": "https://finnhub.io/api/news?id=9e265169b6737d4fa92a811a1bd972b5793b8763d68240b88e58d12902bf1c2b"
    }
  },
  {
    "ts": null,
    "headline": "Moderna explores outside financing for vaccine trials, shares dip",
    "summary": "Investing.com -- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech firm’s effort to align capital efficiency with strategic advancement across its product pipeline amid slowing COVID-19 revenue.",
    "url": "https://finnhub.io/api/news?id=15aa37ec586183190d6e34771b2aa9e2af082bd84192e0186af90e93d83efb1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749741554,
      "headline": "Moderna explores outside financing for vaccine trials, shares dip",
      "id": 135221068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Investing.com -- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech firm’s effort to align capital efficiency with strategic advancement across its product pipeline amid slowing COVID-19 revenue.",
      "url": "https://finnhub.io/api/news?id=15aa37ec586183190d6e34771b2aa9e2af082bd84192e0186af90e93d83efb1a"
    }
  },
  {
    "ts": null,
    "headline": "Novavax's COVID-Flu Combo Shot Shows Strong Immune Response",
    "summary": "NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.",
    "url": "https://finnhub.io/api/news?id=e112e6f6ef39c46e229cbe883e6b9f7496be4ee4eb7774808203678aebfef118",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749730500,
      "headline": "Novavax's COVID-Flu Combo Shot Shows Strong Immune Response",
      "id": 135212799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.",
      "url": "https://finnhub.io/api/news?id=e112e6f6ef39c46e229cbe883e6b9f7496be4ee4eb7774808203678aebfef118"
    }
  },
  {
    "ts": null,
    "headline": "Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025",
    "summary": "CAMBRIDGE - Moderna, Inc. , today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET.A live webcast of...",
    "url": "https://finnhub.io/api/news?id=4d6b37ad2973cd34f3fc4375c9978d72a28de96c287e1ecddce226b2ba48f33b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749724079,
      "headline": "Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025",
      "id": 135212830,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "CAMBRIDGE - Moderna, Inc. , today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET.A live webcast of...",
      "url": "https://finnhub.io/api/news?id=4d6b37ad2973cd34f3fc4375c9978d72a28de96c287e1ecddce226b2ba48f33b"
    }
  },
  {
    "ts": null,
    "headline": "Is it Time to Dump Your Shares of Moderna?",
    "summary": "Moderna stock soared early in the pandemic thanks to sales of its coronavirus vaccine.  After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune.  The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped.",
    "url": "https://finnhub.io/api/news?id=2fafafe235c9a83b89df35f77b5ff5ff2391fa5e08274fdff72bdb0f4523260d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749716700,
      "headline": "Is it Time to Dump Your Shares of Moderna?",
      "id": 135212816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna stock soared early in the pandemic thanks to sales of its coronavirus vaccine.  After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune.  The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped.",
      "url": "https://finnhub.io/api/news?id=2fafafe235c9a83b89df35f77b5ff5ff2391fa5e08274fdff72bdb0f4523260d"
    }
  },
  {
    "ts": null,
    "headline": "US Health Secretary Kennedy's vaccine actions and policy positions",
    "summary": "U.S. Health Secretary Robert F.Kennedy Jr., a long-time vaccine skeptic, has been makingsweeping changes to reshape regulation of vaccines, food andmedicine. The most far-reaching of...",
    "url": "https://finnhub.io/api/news?id=ba25de499f5bfb5d1be353c591e504fd97485c334f4aaabf06fb0e42920d1d8b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749709216,
      "headline": "US Health Secretary Kennedy's vaccine actions and policy positions",
      "id": 135525512,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F.Kennedy Jr., a long-time vaccine skeptic, has been makingsweeping changes to reshape regulation of vaccines, food andmedicine. The most far-reaching of...",
      "url": "https://finnhub.io/api/news?id=ba25de499f5bfb5d1be353c591e504fd97485c334f4aaabf06fb0e42920d1d8b"
    }
  },
  {
    "ts": null,
    "headline": "Vaccine actions and policy positions under US Health Secretary Kennedy",
    "summary": "U.S. Health Secretary Robert F.Kennedy Jr., a long-time vaccine skeptic, has been makingsweeping changes to reshape U.S. regulation of vaccines, foodand medicine. The most...",
    "url": "https://finnhub.io/api/news?id=e94ed3d44cf48d7a0941c8cf8338a19c4e28804fed330767f8975eea307e62a8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749709216,
      "headline": "Vaccine actions and policy positions under US Health Secretary Kennedy",
      "id": 135210661,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F.Kennedy Jr., a long-time vaccine skeptic, has been makingsweeping changes to reshape U.S. regulation of vaccines, foodand medicine. The most...",
      "url": "https://finnhub.io/api/news?id=e94ed3d44cf48d7a0941c8cf8338a19c4e28804fed330767f8975eea307e62a8"
    }
  }
]